Concert Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Concert Pharmaceuticals's estimated annual revenue is currently $15M per year.
- Concert Pharmaceuticals's estimated revenue per employee is $319,149
- Concert Pharmaceuticals's total funding is $204.7M.
Employee Data
- Concert Pharmaceuticals has 47 Employees.
- Concert Pharmaceuticals grew their employee count by -37% last year.
Concert Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | VP, IT and Infrastructure | Reveal Email/Phone |
4 | VP Nonclinical Research & Development | Reveal Email/Phone |
5 | VP Pharmaceutical Development | Reveal Email/Phone |
6 | SVP Regulatory Affairs & Quality Assurance | Reveal Email/Phone |
7 | VP, IT and Infrastructure | Reveal Email/Phone |
8 | Executive Director, Formulation Development | Reveal Email/Phone |
9 | Director, DMPK | Reveal Email/Phone |
10 | Associate Director, Chemical Development | Reveal Email/Phone |
Concert Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Concert Pharmaceuticals?
Concert Pharmaceuticals was co-founded in April 2006 by Roger Tung, Richard Aldrich and Christoph Westphal. Dr. Tung had previously served as Vice President of Drug Discovery at Vertex Pharmaceuticals, and is an inventor of Vertex’s two marketed products. By applying insights derived from existing biologically active compounds, Concert aims to create proprietary and improved medicines while dramatically reducing R&D costs and increasing the probabilities of commercial success.
keywords:Biotechnology, Healthcare
$204.7M
Total Funding
47
Number of Employees
$15M
Revenue (est)
-37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Concert Pharmaceuticals News
According to GlobalData's 'Pharmaceutical Intelligence Center', ... Eli Lilly, Pfizer, Reistone Biopharma, Concert Pharmaceuticals,...
... but have recently announced moves like an acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals,...
Concert Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the...
Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management Lexington, MA (November 4, 2021) - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Part ...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million. In addition, Concert will have the potential to receive an additional $103 million upon the full ...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.5M | 47 | 38% | N/A |
#2 | $6M | 47 | 4% | N/A |
#3 | $9.6M | 47 | 9% | N/A |
#4 | $15M | 47 | 7% | N/A |
#5 | $5.5M | 47 | N/A | N/A |